( Posted by-Desinie Smith)
From the article," According to the report, 48 and 43 percent of surveyed neurologists expect to decrease their first-line use of Copaxone and Avonex, respectively, by 2012, while 45 and 38 percent of respondents expect to increase their third-line use of each respective therapy. Meanwhile, approximately half of surveyed neurologists do not expect to adjust their prescribing of Copaxone, Avonex or any other IFN-beta therapies in any line of treatment over the next two years."

Labels: Avonex